Background: Current antibiotic treatment for Helicobacter pylori infection is often associated with frequent adverse effects and resistance to antibiotics. Alternative treatment methods to control H. pylori infection are needed. Some specific strains of lactic acid bacteria (probiotics) in dairy products are known to inhibit the growth of H. pylori in vitro. A clinical trial was conducted to see the efficacy of a specially designed yogurt product containing specific probiotics on the eradication of H.pylori. Method: The yogurt was prepared using three Lactobacillus spp. (L. acidophilus and L. casei) and one commercial starter culture (L. acidophilus, L. bulgaricus and Streptococcus thermophilus). All these cultures were previously evaluated, and found to have strong in vitro inhibitory effects on the growth of H. pylori. Twenty-seven asymptomatic women positive for H. pylori on gastric biopsy and 13C urea breath test were recruited, and administered 175 ml of the yogurt three times a day for 30 days. The 13C urea breath test was administered again, one month after stopping the yogurt treatment to detect the presence of H. pylori.Results: In 26 of 27 subjects, the urea breath test values remained positive, indicating that the consumption of the yogurt had no effect on the eradication of H. pylori. Conclusion: Although the designed fermented milk containing lactobacilli is very effective in the inhibition of H. pylori growth in vitro, eradication of this infection in humans is difficult to achieve by consuming this product.

Dunn BE, Cohen H, Blaser MJ: Helicobacter pylori. Clin Microbiol Rev 1997;10:720–741.
Ernst PB, Gold BD: The disease spectrum of Helicobacter pylori: The immunopathogenesis of gastroduodenal ulcer and gastric cancer. Annu Rev Microbiol 2000;54:615–640.
Sadowski DC, Fedorak RN, Bailey RJ, Smith L: Alberta Society of Gastroenterolgy consensus statement: Helicobacter pylori in peptic ulcer disease. Can J Gastroenterol 1997;11:544–547.
McNamara D, O’morian C: Consensus guidelines: Agreement and debate surrounding the optimal management of Helicobacter pylori infection. Can J Gastroenterol 2000;114:511–527.
Graham DY: Therapy of Helicobacter pylori: Current status and issues. Gastroenterology 2000;118:52–58.
Lahaie RG, Gaudreau C: Helicobacter pylori antibiotic resistance: Trends over time. Can J Gastroenterol 2000;14:895–899.
Graham DY: Antibiotic resistance in Helicobacter pylori: Implications for therapy. Gastroenterology 1998;115:1272–1277.
Salminen S, Isolauri E, Salminen E: Clinical uses of probiotics for stabilizing the gut mucosal barrier: Successful strains and future challenges. Antonie Van Leeuwenhoek 1996;70:347–358.
Marteau PR, de Vrese M, Cellier CJ, Schrezenmeir J: Protection from gastrointestinal diseases with the use of probiotics. Am J Clin Nutr 2001;73(suppl):430S–436S.
Midolo PD, Lambert JR, Hull R, Luo F, Grayson ML: In vitro inhibition of Helicobacter pylori NCTC 11637 by organic acids and lactic acid bacteria. J Appl Bact 1995;79:475–479.
Coconnier MH, Lievin V, Hemery E, Servin AL: Antagonistic activity against Helicobacter infection in vitro and in vivo by the human L. acidophilus strain LB. App Environ Microbiol 1998;64:4573–4580.
Wendakoon CN, Fedio W, Macloed A, Ozimek, L: In vitro inhibition of Helicobacter pylori by dairy starter cultures. Milchwissenschaft 1998;53:499–502.
Davidson PM, Hoover DG: Antimicrobial compounds from lactic acid bacteria; in Salminen S, Wright A (eds): Lactic Acid Bacteria. New York, Marcel Dekker, 1993, pp 127–159.
Meisel, H: Biochemical properties of regulatory peptides derived from milk proteins. Peptide Sci 1997;43:119–128.
Michetti P, Dorta G, Wiesel PH, Brassart D, Verdu E, Herranz, M, Felley C, Porta N, Rouvet M, Blum AL, Corthésy-Theulaz I: Effect of whey-based culture supernatant Lactobacillus acidophilus (johnsonii) La1 on Helicobacter pylori infection in humans. Digestion 1999;60:203–209.
Mrda Z, Zivanovic M, Rasic J, Gajin S, Somer L, Trbojevic S, Majoros J, Petrovic Z: Therapy of Helicobacter pylori infection using Lactobacillus acidophilus. Med Pregl 1998;51:343–345.
Sakamoto I, Igarashi M, Kimura K, Takagi A, Miwa T, Koga Y: Suppressive effect of Lactobacillus gasseri OLL2716 (LG21) on Helicobacter pylori infection in humans. J Antimicrobial Chemother 2001;47:709–710.
Kabir AMA, Aiba Y, Takagi A, Kamiya S. Miwa T, Koga Y: Prevention of Helicobacter pylori by lactobacilli in a gnotobiotic murine model. Gut 1997;41:49–55.
Lorca GL, Wadström T, deValdez GF, Ljungh Å: Lactobacillus acidophilus autolysins inhibit Helicobacter pylori in vitro. Curr Microbiol 2001;42:39–44.
Dial EJ, Hall LR, Serna H, Romero JJ, Fox JG, Lichtenberger LM: Antibiotic properties of bovine lactoferrin on Helicobacter pylori. Dig Dis Sci 1998;43:2750–2756.
Luo F, Hul RR, Lambert JR: Milk derived substances inhibitory to Helicobacter pylori in vitro (abstracts No 440). Am J Gastroenterol 1994:1395.
Opekun AR, El-Zaimaity HM, Osato MS, Gilger MA, Malaty HM, Terry M, Headon DR, Graham DY: Novel therapies for Helicobacter pylori infection. Aliment Pharm Ther 1999;13:35–42.
Canducci F, Armuzzi A, Cremonni F, Cammarota G. Bartolozzi F, Pola P, Gasbarrini G, Gasbarrini A: A lyophilized and inactivated culture of Lactobacillus acidophilus increase Helicobacter pylori eradication rates. Aliment Pharmacol Ther 2000;14:1625-1629.
Armuzzi A, Cremonini F, Bartolozzi F, Canducci F, Candelli M, Ojetty V, Cammarota G, Anti M, De Lorenzo A, Pola P, Gasbarrini G, Gasbarrini A: The effect of oral administration of Lactobacillus GG on antibiotic associated gastrointestinal side effects during H. pylori eradication therapy. Aliment Pharmacol Ther 2001;15:163–169.
You do not currently have access to this content.